Joint Pain Injections Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type of Injection, By Application, By Region & Competition, 2021-2031F

The global market for joint pain injections is projected to expand from USD 4.72 billion in 2025 to USD 7.39 billion by 2031, reflecting a compound annual growth rate of 7.76%. These therapeutic procedures involve the direct delivery of analgesic or anti-inflammatory medications into the synovial joint space to alleviate musculoskeletal pain and enhance mobility. The sector's growth is primarily fueled by the aging global population and the rising prevalence of osteoarthritis, which creates a strong need for effective non-surgical management options. Data from Arthritis UK indicates that over 10 million individuals in the United Kingdom were living with arthritis in 2025, highlighting the critical demand for symptomatic relief therapies that bridge the gap between oral pharmaceuticals and invasive surgeries.

However, the market encounters a significant obstacle regarding the safety profile of long-term intra-articular corticosteroid use. Repeated administration of these agents carries risks such as joint infection and cartilage degradation, factors that often discourage sustained clinical application. Consequently, healthcare providers are compelled to restrict the frequency of usage, which poses a notable challenge to the consistent growth of the injection therapy sector.

Market Driver

The rising incidence of rheumatoid arthritis and osteoarthritis serves as the primary engine for the Global Joint Pain Injections Market. As the worldwide population ages, the burden of degenerative joint conditions increases, generating a steady demand for non-surgical symptom relief. This demographic shift forces healthcare systems to prioritize injectable therapies, such as hyaluronic acid and corticosteroids, to manage pain and postpone invasive procedures like total knee arthroplasty. A June 2025 report from the Centers for Disease Control and Prevention, titled 'Preventing Chronic Disease', noted that the crude prevalence of diagnosed arthritis among U.S. adults aged 20 and older reached 27.9%, underscoring the vital need for effective intra-articular treatments to support workforce productivity and quality of life.

Additionally, surging global obesity rates are accelerating joint degeneration and propelling market expansion by lowering the average age of arthritis onset. Excess body weight places severe mechanical stress on weight-bearing joints, hastening cartilage breakdown and necessitating earlier therapeutic intervention. In March 2025, the World Obesity Federation's 'World Obesity Atlas 2025' projected that the number of adults living with obesity globally would rise to 1.13 billion by 2030. This trend correlates with increased musculoskeletal comorbidities, prompting pharmaceutical developers to broaden their pain management portfolios. Reflecting this, Anika Therapeutics reported in 2025 that revenue for its international osteoarthritis pain management products grew by 17% in 2024 compared to the previous year.

Market Challenge

The principal hurdle restraining the growth of the global joint pain injections market is the safety concern surrounding the prolonged use of intra-articular corticosteroids. Although these agents offer effective temporary relief, their sustained administration is limited by risks such as cartilage degradation and joint infections. As a result, healthcare professionals are forced to cap the frequency of treatments, often restricting patients to a specific quota of injections per year. This safety ceiling prevents the therapy from becoming a continuous solution for chronic pain management, thereby limiting revenue volume per patient and reducing overall market penetration compared to oral analgesics, which can be taken daily without similar procedural constraints.

This restriction is particularly significant given the vast patient population requiring consistent pain management. According to the Centers for Disease Control and Prevention, 21.3% of adults in the United States had diagnosed arthritis in 2025. This statistic highlights a massive demographic seeking relief; however, the inability to safely administer corticosteroid injections frequently creates a major bottleneck in service delivery. The disparity between the high prevalence of the condition and the restricted usage frequency of the treatment directly hampers the market's ability to fully capitalize on the demand for effective musculoskeletal therapies.

Market Trends

The market is being reshaped by the adoption of orthobiologics and regenerative medicine, as clinicians increasingly prioritize tissue repair over temporary symptom management. This trend involves integrating biologic solutions, such as platelet-rich plasma and hyaluronic acid-based scaffolds, which are designed to restore damaged cartilage and delay joint replacement surgeries. Healthcare providers are swiftly incorporating these therapies into treatment protocols to address the root causes of joint degeneration rather than merely masking pain. In its 'Third Quarter 2025 Financial Results' from November 2025, Anika Therapeutics reported a 25% revenue increase in its Regenerative Solutions segment, driven largely by the market success of the Integrity Implant System and strong international adoption of Hyalofast.

A concurrent shift toward single-injection viscosupplementation regimens is gaining traction due to the demand for reduced clinical burden and greater patient convenience. Unlike traditional multi-injection courses that require repeated hospital visits, single-injection high-molecular-weight hyaluronic acid formulations provide sustained therapeutic benefits in a unified administration. This approach improves operational efficiency for medical practices and enhances patient compliance, making it a preferred option for managing knee osteoarthritis. According to Bioventus's November 2025 'Third Quarter Financial Results', global revenue for its Pain Treatments segment accelerated by 6.4%, primarily fueled by robust U.S. demand for Durolane, a differentiated single-injection hyaluronic acid therapy.

Key Market Players

• Anika Therapeutics Inc
• Bioventus LLC
• Ferring Pharmaceuticals Inc
• Sanofi SA
• Pfizer Inc
• Eli Lilly & Co
• Flexion Therapeutics Inc
• Teva Pharmaceutical Industries Ltd
• Zimmer Biomet Holdings, Inc.

Report Scope

In this report, the Global Joint Pain Injections Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Joint Pain Injections Market, By Type of Injection

• Steroid Joint Injections
• Hyaluronic Acid Injections
• Platelet-rich Plasma (PRP) Injections
• Placental Tissue Matrix (PTM) Injections
• Others

Joint Pain Injections Market, By Application

• Shoulder & Elbow
• Knee & Ankle
• Spinal Joints
• Hip Joint
• Others

Joint Pain Injections Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Joint Pain Injections Market.

Available Customizations:

Global Joint Pain Injections Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).